trending Market Intelligence /marketintelligence/en/news-insights/trending/B_yRydRWQ6gP_xBAjDn6VA2 content esgSubNav
In This List

TransEnterix's Senhance Ultrasonic system for robotic surgeries gets FDA nod

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


TransEnterix's Senhance Ultrasonic system for robotic surgeries gets FDA nod

TransEnterix Inc.'s Senhance Ultrasonic system, part of the company's robotic surgery platform for use in minimally invasive surgeries, has been approved by the U.S. Food and Drug Administration.

The Morrisville, N.C.-based medical device maker said in a Jan. 15 press release that the addition of ultrasonic technology was a significant expansion to its Senhance system, which is the first abdominal robotic surgery platform to receive FDA clearance since 2000.

The Senhance system itself is already cleared in the U.S. for laparoscopic colorectal, gynecological, inguinal hernia and gallbladder removal surgery. With the FDA nod, the Senhance Ultrasonic system is now available in the U.S., as well as all countries that accept a CE Mark designation for the product.

TransEnterix said advanced energy devices, including ultrasonic devices, are critical tools for surgeons in minimally invasive surgery as they deliver controlled energy to effectively ligate and divide tissue, while minimizing thermal injury to surrounding areas.